CSTS Health Care is a Toronto based next-generation oncology biotech disrupting the standard of care with precision treatments that allow individuals to continue living their lives, despite a cancer diagnosis. Cancer need not be a terminal diagnosis, but rather a manageable and treatable disease. Our vision is enabled by a new class of precision oncology agents which allow treatments using any combinations of drugs without the negative side effects associated with using multiple cancer treatments together. To optimizes therapeutic target combinations for difficult to treat cancers and to identify novel genomic based diagnostic biomarkers, CSTS has developed the Aiomic target selection platform. Used together, CSTS technologies enable therapy options that don’t make trade-offs between efficacy and negative side effects.